
“I will be back in an executive role,” David Solomon told MedWatch in November when Zealand Pharma announced he would be stepping back from the company from January 15th – and this weekend he made good on that promise.
The Norway-based biotech company Bionor Pharma announced that David Solomon would take over as CEO of the company, which boasts a market cap of USD 77.5 million against Zealand’s market cap of USD 339 million.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app